Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer

Journal of Nutritional Science and Vitaminology

Volumn 60, Issue 4, 2014, Pages 276-282

  Mitani, Takakazu ^a   Harada, Naoki ^a   Tanimori, Shinji ^a   Nakano, Yoshihisa ^b   Inui, Hiroshi ^a   Yamaji, Ryoichi ^a  

^a Osaka Prefecture University   (Japan)

^b Osaka Shin Ai Junior College   (Japan)

Author keywords

Androgen receptor; Castration resistant prostate cancer; Hypoxia inducible factor 1 ; Resveratrol; catenin

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEASOME INHIBITOR; RESVERATROL; VASCULOTROPIN; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; PLANT EXTRACT; STILBENE DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL FRACTIONATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE MICROSCOPY; MALE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL NUCLEUS; CHEMISTRY; DIET; GENETICS; METABOLISM; NUDE MOUSE; PHYTOTHERAPY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE; VITIS;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; DIET; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE, INBRED BALB C; MICE, NUDE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; STILBENES; TRANSCRIPTIONAL ACTIVATION; VITIS;

EID: 84923486099     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.60.276     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–2917.
2. Heemers HV, Tindall DJ. 2007. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28: 778–808.
3. Wissmann M, Yin N, Müller JM, Greschik H, Fodor BD, Jenuwein T, Vogler C, Schneider R, Günther T, Buettner R, Metzger E, Schüle R. 2007. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptordependent gene expression. Nat Cell Biol 9: 347–353.
4. Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K. 2007. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J Urol 178: 1282–1288.
5. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. 2009. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6: 76–85.
6. Debes JD, Tindall DJ. 2004. Mechanisms of androgenrefractory prostate cancer. N Engl J Med 351: 1488–1490.
7. Rudolfsson SH, Bergh A. 2008. Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1alpha. J Endocrinol 196: 11–19.
8. Shabsigh A, Ghafar MA, de la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG, Buttyan R. 2001. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 81: 437–444.
9. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. 2009. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res 69: 4708–4715.
10. Mitani T, Yamaji R, Higashimura Y, Harada N, Nakano Y, Inui H. 2011. Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor1a in a low androgen environment. J Steroid Biochem Mol Biol 123: 58–64.
11. Mitani T, Harada N, Nakano Y, Inui H, Yamaji R. 2012. Coordinated action of hypoxia-inducible factor-1a and β-catenin in androgen receptor signaling. J Biol Chem 287: 33594–33606.
12. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. 2010. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54: 7–16.
13. Leifert WR, Abeywardena MY. 2008. Cardioprotective actions of grape polyphenols. Nutr Res 28: 729–737.
14. Gresele P, Cerletti C, Guglielmini G, Pignatelli P, de Gaetano G, Violi F. 2011. Effects of resveratrol and other wine polyphenols on vascular function: an update. J Nutr Biochem 22: 201–211.
15. Kim H, Hall P, Smith M, Kirk M, Prasain JK, Barnes S, Grubbs C. 2004. Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. J Nutr 134: 3445S–3452S.
16. Wang TT, Schoene NW, Kim YS, Mizuno CS, Rimando AM. 2010. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells. Mol Nutr Food Res 54: 335–344.
17. Filomeni G, Graziani I, Rotilio G, Ciriolo MR. 2007. trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr 2: 295–305.
18. Araújo JR, Gonçalves P, Martel F. 2011. Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr Res 31: 77–87.
19. Yamaji R, Fujita K, Takahashi S, Yoneda H, Nagao K, Masyda W, Naito M, Tsuruo T, Miyatake K, Inui H, Nakano Y. 2003. Hypoxia up-regulates glyceraldehyde3-phosphate dehydrogenase in mouse brain capillary endothelial cells: involvement of Na1/Ca21 exchanger. Biochim Biophys Acta 1593: 269–276.
20. Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe, Y, Sakaue M, Sano T, Kitagawa T, Himeno S, Imura N, Hara S. 2007. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 5: 383–391.
21. Valenta T, Hausmann G, Basler K. 2012. The many faces and functions of β-catenin. EMBO J 31: 2714–2736.
22. Wang G, Wang J, Sadar MD. 2008. Crosstalk between the androgen receptor and beta-catenin in castrateresistant prostate cancer. Cancer Res 68: 9918–9927.
23. de la Taille A, Rubin MA, Chen MW, Vacherot F, deMedina SG, Burchardt M, Buttyan R, Chopin D. 2003. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 9: 1801–1807.
24. Kaidi A, Williams AC, Paraskeva C. 2007. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9: 210–217.
25. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato SY, Shirai T. 2007. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 9: 7–14.
26. Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, Lamartiniere CA. 2007. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28: 1946–1953.
27. Horn TL, Cw Delmas D, Lin HY. 2011. Role of membrane dynamics processes and exogenous molecules in cellular resveratrol uptake: consequences in bioavailability and activities. Mol Nutr Food Res 55: 1142–1153.
28. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377–1382.
29. de Boer VC, Dihal AA, van der Woude H, Arts IC, Wolffram S, Alink GM, Rietjens IM, Keijer J, Hollman PC. 2005. Tissue distribution of quercetin in rats and pigs. J Nutr 135: 1718–1725.
30. Abd El-Mohsen M, Bayele H, Kuhnle G, Gibson G, Debnam E, Kaila Srai S, Rice-Evans C, Spencer JP. 2006. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br J Nutr 96: 62–70.
31. Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI. 2013. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 29: 178–183.
32. Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, Shibata N, Kobayashi M, Kanayama M, Uchida K, Terao J. 2008. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem 283: 9424–9434.
33. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. 2008. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF1alpha. Nature 453: 807–811.
34. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. 2010. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302–305.
35. Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC. 2008. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog 47: 686–700.
36. Singh-Gupta V, Zhang H, Yunker CK, Ahmad Z, Zwier D, Sarkar FH, Hillman GG. 2010. Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy. Pharm Res 27: 1115–1127.
37. Lee DH, Lee YJ. 2008. Quercetin suppresses hypoxiainduced accumulation of hypoxia-inducible factor1alpha (HIF-1αlpha) through inhibiting protein synthesis. J Cell Biochem 105: 546–553.
38. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. 2005. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4: 1465–1474.
39. Cao Z, Fang J, Xia C, Shi X, Jiang BH. 2004. trans-3,4′,5-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 10: 5253–5263.
40. Hong KS, Park JI, Kim MJ, Kim HB, Lee JW, Dao TT, Oh WK, Kang CD, Kim SH. 2012. Involvement of SIRT1 in hypoxic down-regulation of c-Myc and β-catenin and hypoxic preconditioning effect of polyphenols. Toxicol Appl Pharmacol 259: 210–218.